Skip to main content
. 2022 Jul 4;3(8):927–931. doi: 10.1038/s43018-022-00400-2

Fig. 1. Clinical response and change in tumor volume by MRI and ultrasound, and clinical and pathological response patient journeys by MRI.

Fig. 1

a, Response by MRI at the end of cycle 2 of niraparib. b, Response by ultrasound after cycles 1 and 2. c, Presence of pCR, defined as ypT0/Tis ypN0, made at the time of surgery (n = 21 patients). EOT, end of treatment; NE, not evaluable; SI, stage I; SII, stage II; SIII; stage III.

Source data